PARD (Poniard Pharmaceuticals) Total Stockholders Equity: $3.12 Mil (As of Sep. 2011)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Poniard Pharmaceuticals Total Stockholders Equity?

Poniard Pharmaceuticals PARD Total Stockholders Equity is $3.12 Mil as of Sep. 2011.

Poniard Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2011 was $3.12 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Poniard Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2011 was $2.08. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Poniard Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2011 was 0.53.

Poniard Pharmaceuticals  (OTCPK:PARD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Poniard Pharmaceuticals's Book Value per Share for the quarter that ended in Sep. 2011 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(3.117-0.002)/1.499
=2.08

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Poniard Pharmaceuticals's Debt-to-Equity for the quarter that ended in Sep. 2011 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 1.64) / 3.117
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Total Stockholders Equity Related Terms

Poniard Pharmaceuticals Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals Total Stockholders Equity Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.89 89.11 47.65 23.64 8.45

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.13 8.45 9.34 6.28 3.12
What does a Total Stockholders Equity of $3.12 Mil mean?
Poniard Pharmaceuticals (PARD) has a Total Stockholders Equity of $3.12 Mil as of Sep. 2011. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' Total Stockholders Equity too high?
Poniard Pharmaceuticals' current Total Stockholders Equity is $3.12 Mil.
How does Poniard Pharmaceuticals' Total Stockholders Equity compare to OBMP and NSPX?
Poniard Pharmaceuticals' Total Stockholders Equity of $3.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current Total Stockholders Equity is $3.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current Total Stockholders Equity of $3.12 Mil. The current Total Stockholders Equity is $3.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current Total Stockholders Equity is $3.12 Mil as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.